ArdorComm Media Group

Saturday, November 21, 2026 8:32 PM

Health & Wellness Community

India Records 38% Decline in TB Mortality Since 2015, WHO Report Shows

India has recorded a 38 per cent decline in tuberculosis (TB)-related deaths since 2015, surpassing the global reduction of 35 per cent, according to the World Health Organization’s (WHO) Global Tuberculosis Report 2026. The country has also achieved a 94 per cent treatment success rate among patients with drug-susceptible TB. The report highlights that the South-East Asia Region accounted for the largest share of new TB cases globally in 2025, at 35 per cent, followed by the Western Pacific Region at 27 per cent and the African Region at 25 per cent. Around 88 per cent of newly reported TB cases were concentrated in 30 countries. India alone contributed approximately a quarter of the global burden, followed by Indonesia (10 per cent), the Philippines (6.8 per cent), China (6.5 per cent), Pakistan (6.4 per cent), Nigeria (4.9 per cent), the Democratic Republic of the Congo (3.9 per cent) and Bangladesh (3.7 per cent). The five countries with the highest burden collectively accounted for 55 per cent of global cases. Globally, TB continues to impose a significant financial burden on affected households. Nearly half of people receiving TB treatment and their families face catastrophic expenses, exceeding 20 per cent of their total household income, when medical and non-medical costs and income losses are taken into account. The report also identifies several factors that increase the risk of developing TB, including HIV infection, undernutrition, diabetes and tobacco use. An estimated 9.6 lakh new cases were linked to undernutrition, 9.2 lakh to diabetes, 7.3 lakh to alcohol use disorders, 6.9 lakh to smoking and 5.5 lakh to HIV infection. Worldwide, approximately 10.6 million people developed TB in 2025, including 5.7 million men, 3.7 million women and 1.2 million children. The disease claimed an estimated 1.13 million lives during the year, remaining the world’s leading cause of death from a single infectious agent. Drug-resistant tuberculosis, particularly multidrug-resistant TB (MDR-TB), continues to pose a serious public health and health security challenge. Only around two in five people diagnosed with drug-resistant TB received treatment in 2025. However, global interventions against the disease have helped save an estimated 86 million lives since 2000. In India, the TB Mukt Bharat Abhiyaan has expanded screening efforts significantly. Between December 7, 2024, and November 8, 2026, the campaign brought more than 25 crore individuals within the ambit of TB screening activities. According to the Union Health Ministry, the decline in TB mortality has been driven by interventions under the National TB Elimination Programme (NTEP). These include active case detection using AI-enabled X-rays, rapid diagnostic services, timely treatment initiation, differentiated care and nutritional assistance through the Nikshay Poshan Yojana and Nikshay Mitra initiative. The ministry also highlighted the use of artificial intelligence tools to identify disease hotspots, predict high-risk patients likely to experience adverse outcomes and support patient engagement through Khushi, an AI-powered chatbot and avatar-based videobot. Tuberculosis is a bacterial infectious disease that primarily affects the lungs and spreads through the air when an infected person coughs, sneezes or spits. Despite its continued global impact, the disease is both preventable and curable. Source: The Hindu  

India Records 38% Decline in TB Mortality Since 2015, WHO Report Shows Read More »

India needs specific PM2.5 reduction targets to combat air pollution: FICCI-EY report

India must adopt a health-focused strategy to tackle air pollution, with clearly defined targets for reducing fine particulate matter (PM2.5) under the National Clean Air Programme (NCAP), according to a new knowledge paper by FICCI and EY titled “Clean Air, Healthy India.” The report highlights the serious public health consequences of air pollution, noting that more than two million deaths in India were attributed to pollution in 2023. It identifies PM2.5 particles, which measure 2.5 microns or less, as a major health concern because they can penetrate deep into the lungs and enter the bloodstream. Long-term exposure to these pollutants is linked to respiratory diseases, cardiovascular conditions, strokes and cognitive impairment. The resulting health burden also increases healthcare costs and affects workforce productivity. Dr. Ashutosh Raghuvanshi, Chair of the FICCI Health Services Committee and MD and CEO of Fortis Healthcare, emphasised that clean air should be treated as a central public health priority rather than solely an environmental concern. He highlighted the role of healthcare institutions in raising public awareness, monitoring pollution-related illnesses and improving healthcare preparedness. He also called for stronger cooperation among government, industry and healthcare providers to achieve measurable health improvements. Similarly, Dr. Arun Agarwal, Chair of the FICCI Working Group on Air Pollution (Healthcare Perspective), former Dean of MAMC and Medical Advisor to Apollo Hospitals Group, stressed the need to move beyond seasonal measures and make pollution exposure reduction a year-round public health priority. He underlined the importance of integrating air-quality monitoring with health surveillance, strengthening preventive measures and developing interventions based on local pollution sources. Ahead of the peak pollution season, FICCI-EY has called for immediate action and outlined 10 practical recommendations to address major sources of emissions. Among the proposed measures is the introduction of closed-loop dust management systems at large construction sites to control construction and demolition pollution. The report also recommends identifying pollution hotspots associated with traffic, industrial activity, construction and waste burning, followed by testing targeted interventions. To reduce vehicular emissions, the paper suggests deploying smart traffic signals to minimise congestion, vehicle idling and stop-start traffic. For industrial and backup-power pollution, it recommends using real-time stack-emission data to strengthen industrial pollution management, upgrading conventional brick kilns to zigzag firing technology and replacing diesel-based backup power systems with battery-hybrid alternatives. The report further advocates technology-driven solutions to monitor and control industrial emissions, diesel soot and pollution in areas with high human exposure. Addressing agricultural and waste-related pollution, the recommendations include converting crop residue into fuel and commercially viable products to reduce stubble burning. It also proposes using recovered plastic, industrial waste and construction and demolition debris in building houses and infrastructure. The FICCI-EY paper emphasises that effective implementation will require clear government standards and consistent regulatory frameworks. It calls on industries to prioritise efficiency, competitiveness and innovation, while healthcare institutions strengthen health surveillance and public advisories. The report also highlights the importance of community participation, stressing that people must have access to reliable information and opportunities to contribute to local clean-air initiatives. Source: Economic Times

India needs specific PM2.5 reduction targets to combat air pollution: FICCI-EY report Read More »

Government proposes immediate suspension of manufacturing licences for substandard drugs

The Union Health Ministry has proposed changes to the Drugs Rules, 1945, that would allow authorities to immediately suspend the manufacturing licences of pharmaceutical companies producing medicines that fail to meet specified critical quality standards. The proposed amendments, announced on November 4, 2026, aim to strengthen drug quality monitoring, enable faster regulatory action against substandard medicines and prevent potentially unsafe products from remaining in circulation. Under the existing rules, suspension or cancellation of a drug manufacturing licence generally involves a prescribed regulatory process, including the issuance of a show-cause notice. This can create a delay between the identification of a Not of Standard Quality (NSQ) drug and the initiation of action, during which the medicine may continue to be available in the market. To address this gap, the ministry has proposed empowering the Central Licensing Approving Authority or the concerned State Licensing Authority to immediately suspend a drug’s manufacturing licence after receiving a Government Analyst’s report declaring it NSQ on specified parameters. These include assay, dissolution, related substances, impurities and sterility. According to the ministry, failures involving these parameters can directly affect medicine quality and patient safety, requiring immediate regulatory intervention. Manufacturers must implement corrective measures The proposed framework also specifies conditions for revoking a suspension. Manufacturers will be required to conduct a comprehensive root cause analysis to identify the reasons behind the quality failure and implement appropriate Corrective and Preventive Action (CAPA). The suspension will remain in force until the licensing authority is satisfied that the necessary corrective measures have been implemented and verified. This is intended to ensure that quality deficiencies are properly addressed and measures are taken to prevent similar failures in the future. The ministry has also proposed changes to Form 13, which covers Government Analyst test reports, to improve communication and coordination among regulatory authorities and industry stakeholders. Under the revised mechanism, copies of NSQ reports will be sent to the Drugs Controller General of India (DCGI), the relevant State or Union Territory Licensing Authority overseeing the manufacturing facility, and the manufacturer and marketer of the concerned medicine. The government said the arrangement would facilitate faster information sharing, coordinated regulatory action and greater accountability across the pharmaceutical manufacturing and distribution chain. Draft amendments open for public consultation The proposed changes follow discussions at the 65th meeting of the Drugs Consultative Committee held on December 20, 2024, and recommendations made during the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025. The amendments are expected to improve post-marketing drug surveillance, strengthen action against manufacturers of substandard medicines and enhance accountability among pharmaceutical companies and marketers. The draft rules have been released for public consultation. Stakeholders and members of the public can submit their objections and suggestions within 30 days from the date on which the relevant Gazette of India notification becomes available. Source: The Hindu

Government proposes immediate suspension of manufacturing licences for substandard drugs Read More »

Max Healthcare reports ₹3,219 crore revenue in Q2 FY27, net profit rises 10%

Max Healthcare reported a 20 per cent year-on-year (YoY) increase in gross revenue to ₹3,219 crore for the second quarter of FY27. The healthcare provider recorded a network profit after tax (PAT) of ₹448 crore, registering a 10 per cent growth compared with the corresponding quarter of the previous financial year. As of September 2026, the company’s operational bed capacity reached 5,518, marking an addition of 758 beds and a 16 per cent increase over September 2025. Bed occupancy during the quarter stood at 77 per cent, while Occupied Bed Days (OBDs) increased by 13 per cent YoY. Average Revenue Per Patient (ARPP) for Q2 FY27 was ₹2.31 lakh, compared with ₹2.14 lakh in the year-ago quarter and ₹2.30 lakh in Q1 FY27, reflecting an annual growth of 8 per cent. The company’s non-captive pathology business, Max Lab, generated gross revenue of ₹66 crore during the quarter, registering a 24 per cent YoY and 15 per cent quarter-on-quarter (QoQ) increase. Operating across more than 63 cities, the vertical offers over 2,700 diagnostic tests. Max Healthcare’s home care division, Max@home, also recorded strong growth, with gross revenue increasing 37 per cent YoY to ₹86 crore. Revenue grew 10 per cent sequentially, supported by demand for physiotherapy and rehabilitation, nursing services, attendants, sample collection and medicine delivery. Free cash generation during the quarter stood at ₹500 crore, compared with ₹291 crore in Q2 FY26 and ₹397 crore in Q1 FY27. The company invested ₹292 crore in ongoing expansion projects and distributed ₹195 crore towards dividends. On the infrastructure front, Max Super Speciality Hospital (MSSH), Dwarka, has commenced operations at its Oncology Block. The development is expected to take the hospital’s overall capacity to 318 beds during Q3 FY27. The company also strengthened its stake in Kalinga Hospital Limited (KHL), increasing its shareholding from approximately 58.28 per cent to 66.34 per cent following a rights issue on September 7, 2026. KHL operates a 250-bed hospital in Bhubaneswar. Additionally, Max Healthcare has approved a capital expenditure of ₹415 crore for adding 209 beds across its existing hospitals. The planned expansion includes 85 beds at MSSH, Noida, 60 beds at MSSH, Vaishali and 64 beds at BLK-Max Hospital. The BLK-Max expansion will also include a multi-level car parking facility to accommodate the growing number of patients and visitors. For the six months ended September 2026, the company’s total bed capacity stood at 6,184, representing a 20 per cent YoY increase. Network gross revenue for the period reached ₹6,200 crore, up 18 per cent from the corresponding period last year, primarily driven by higher Occupied Bed Days. Network PAT for the first half of FY27 increased 7 per cent to ₹805 crore, compared with ₹750 crore in the corresponding period of the previous financial year on a like-for-like basis. Cash generated from operations during the six-month period amounted to ₹897 crore, while net debt stood at ₹2,369 crore. Commenting on the performance, Abhay Soi, Chairman and Managing Director of Max Healthcare, said the company continued to register steady growth while expanding bed capacity across multiple locations to address India’s increasing demand for quality healthcare. He highlighted that higher occupancy across network hospitals and the faster utilisation of newly added beds reflected strong demand for the company’s services. He also noted growing momentum in medical value travel, supported by India’s cost-competitive healthcare offerings, which is further enhancing the country’s position as a global healthcare destination. Source: Economic Times  

Max Healthcare reports ₹3,219 crore revenue in Q2 FY27, net profit rises 10% Read More »

ICMR Funds Four-Year Study to Explore Genetic Links and Potential Treatments for Autoimmune Diseases

The Indian Council of Medical Research (ICMR) has funded a four-year research project to investigate the genetic and immunological factors behind autoimmune diseases, with the aim of identifying shared disease mechanisms and potential targets for future therapies. The study will focus on families with multiple members affected by autoimmune conditions. Researchers are planning to develop a nationwide cohort of 200 families, each having at least one member diagnosed with systemic lupus erythematosus (SLE), commonly known as lupus. Doctors at the All India Institute of Medical Sciences (AIIMS), New Delhi, have also appealed to eligible lupus patients to participate in the research. Titled ‘Genomic Profiling and Identification of Targetable Shared Immunopathogenic Events in Multiplex Families with Autoimmune Diseases’, the project has been awarded to Dr Dipyaman Ganguly of Ashoka University, Sonipat, and Dr Ranjan Gupta, Additional Professor in the Department of Rheumatology at AIIMS Delhi. As part of the investigation, researchers will conduct genetic and immunological assessments of patients and their family members to identify common biological processes associated with the development of autoimmune conditions. The findings are expected to improve understanding of disease mechanisms and help identify potential targets for developing new treatment approaches. Autoimmune diseases develop when the body’s immune system mistakenly attacks its own healthy cells and tissues. According to Dr Gupta, a family history of these conditions is associated with an increased risk, making genetic and shared immunological factors important areas of investigation. The research will involve six clinical centres across the country: AIIMS Delhi, AIIMS Bibinagar in Telangana, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) in Lucknow, St John’s Hospital in Bengaluru, Nizam’s Institute of Medical Sciences in Hyderabad and Kolkata Medical College. These institutions will contribute clinical information and biological samples to support the study. Patients diagnosed with lupus and residing in the Delhi-NCR region can contact the AIIMS Delhi centre to enquire about eligibility and enrolment. Participation will depend on meeting the study’s clinical and other recruitment requirements. Through this multi-institutional initiative, researchers aim to strengthen understanding of the inherited and immune-related factors associated with autoimmune diseases and explore new possibilities for targeted treatment. Source: PTI

ICMR Funds Four-Year Study to Explore Genetic Links and Potential Treatments for Autoimmune Diseases Read More »

Fortis Healthcare CEO Calls for Periodic Revision of Government Health Insurance Rates

Ashutosh Raghuvanshi, Managing Director and CEO of Fortis Healthcare, has called for regular revisions of package rates under government-sponsored health insurance schemes to keep pace with rising medical costs, advancements in healthcare technology and the growing demand for quality treatment. Speaking at the 20th edition of FICCI Heal 2026, Raghuvanshi emphasised the need to periodically reassess reimbursement rates under the Central Government Health Scheme (CGHS) and the Pradhan Mantri Jan Arogya Yojana (PMJAY). He also highlighted the importance of timely hospital claim settlements, stating that a transparent and predictable reimbursement mechanism could encourage greater private sector participation and support investment in healthcare infrastructure. The remarks come a year after the Union Health Ministry revised package rates for nearly 2,000 procedures under CGHS in October 2025. The revision marked the first major overhaul of the rates since 2014. Following the announcement, Nathealth, an industry body representing private healthcare providers, welcomed the decision and called for government-sponsored health insurance rates to be periodically aligned with the Consumer Price Index. The viability of reimbursement rates remains a key concern for private healthcare providers. Major listed hospital chains, including Fortis Healthcare, Max Healthcare and Apollo Hospitals, do not participate in the Ayushman Bharat scheme. Industry representatives have argued that reimbursement rates must be financially sustainable, particularly for corporate hospitals operating in urban areas, to encourage their participation. Raghuvanshi also urged the government to reconsider the taxation framework applicable to hospitals. Although healthcare services are exempt from the Goods and Services Tax (GST), hospitals generally cannot claim input tax credit on goods and services used to provide these exempt services. This results in additional costs for healthcare providers and can constrain their ability to invest in expansion and infrastructure. He said reviewing the existing tax structure could ease cost pressures on hospitals while strengthening their capacity to deliver affordable, high-quality healthcare services. Source: Economic Times

Fortis Healthcare CEO Calls for Periodic Revision of Government Health Insurance Rates Read More »

Mid-Career Professionals to Account for 93% of Healthcare GCC Hiring Demand in 2026: Report

Mid-career professionals are expected to dominate recruitment at healthcare Global Capability Centres (GCCs) in India in 2026, accounting for nearly 93% of hiring demand, according to a report by staffing and workforce solutions firm Quess Corp. The sector is projected to generate around 67,000 job openings during the year. The findings are outlined in Quess Corp’s India Healthcare GCC Outlook 2026, which draws on secondary research, job postings across multiple recruitment platforms and publicly available information. The report highlights the growing demand for professionals with three to 12 years of experience, as companies increasingly prioritise specialised skills and industry expertise. India’s healthcare GCC ecosystem has expanded to 155 organisations employing approximately 3.2 lakh professionals. These centres are moving beyond conventional support operations towards artificial intelligence (AI), scientific research, clinical development and digital health services. Recruitment demand is increasingly focused on specialised roles in AI, data analytics, clinical research and regulatory functions. However, the report points to a widening talent shortage in these areas, with the supply of suitably qualified professionals struggling to meet industry requirements. Bengaluru and Hyderabad remain major hubs for healthcare GCCs, together accounting for 62.2% of the existing workforce and 58.4% of projected hiring demand in 2026. Kapil Joshi, CEO of Quess IT Solutions, said hiring in India’s healthcare GCC sector nearly doubled in the previous year, but the availability of skilled professionals remains a significant challenge. He noted that the AI and data segment has only 1.6 professionals available for every job opening, while employers increasingly seek mid-career specialists who combine technological expertise with an understanding of healthcare regulations. Joshi added that as fresher recruitment slows, companies need to focus on developing the next generation of specialised professionals to address future workforce requirements. Source: PTI Tags: 

Mid-Career Professionals to Account for 93% of Healthcare GCC Hiring Demand in 2026: Report Read More »

FSSAI Warns Food Companies Over Non-Compliance with Labelling Norms for Health Supplements

The Food Safety and Standards Authority of India (FSSAI) has raised concerns over food businesses failing to comply with mandatory labelling requirements for nutraceuticals, health supplements and other specialised food products. The regulator has warned of action against businesses that do not follow the prescribed rules. In an advisory shared on social media on Monday, FSSAI highlighted the need to comply with labelling requirements and display appropriate warning statements for plant-based and botanical ingredients, including their extracts. The regulator said several Food Business Operators (FBOs) involved in manufacturing and selling nutraceuticals, health supplements, foods for special dietary use and foods for special medical purposes were not following the stipulated labelling standards and warning requirements. These products are governed by the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016. The regulations cover categories such as health supplements, functional foods, products containing prebiotic and probiotic ingredients, and novel foods. According to FSSAI, the framework specifies permissible limits for plant and botanical ingredients and their extracts, whether used individually or in combination with other ingredients. The regulations also prescribe strict labelling standards and prohibit products from making medicinal claims or suggesting that they can cure diseases. Warning statements must be clearly visible, legible and prominently displayed to help prevent misuse, particularly among vulnerable consumers. FSSAI has urged food businesses to ensure compliance with the applicable requirements, emphasising the importance of accurate product labelling and appropriate warnings to safeguard consumer health and safety. Source: PTI

FSSAI Warns Food Companies Over Non-Compliance with Labelling Norms for Health Supplements Read More »

Maharashtra to Introduce Digital Milk Tracking System to Combat Adulteration

Maharashtra is planning to introduce a digital milk-tracking mechanism within the next six months to a year to strengthen food safety and curb adulteration. The proposed system will enable authorities to trace milk from dairies and collection centres back to the individual animal, Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe said. Speaking at the India Today Conclave Mumbai 2026, Mundhe said the FDA had initiated inspections at milk collection centres across the state to identify adulteration, unsafe milk and violations of prescribed hygiene and handling standards. The proposed digital system will use animal identification data, including details recorded on ear tags, to establish a link between milk production and the animals from which the milk originates. The FDA plans to coordinate with the Animal Husbandry Department to match animal records with milk production data, helping officials identify discrepancies and trace the source of potentially adulterated milk. Mundhe said the department had identified hundreds of milk collection centres for inspection around 15 days earlier, with enforcement teams working to trace milk supplies back to individual farmers. He added that collection centres, chilling facilities and dairies previously found violating regulations had begun improving compliance following inspections and enforcement measures. FDA Calls for Greater Public Participation in Food Safety The FDA commissioner emphasised that food safety requires collective responsibility from consumers, food businesses and government agencies rather than relying solely on individual officials. He noted that safe food practices have implications for public health, economic development, farmers and the country’s overall growth. According to Mundhe, awareness and compliance are gradually expanding across the food sector, from street food vendors to established businesses, although the pace of improvement differs. He also highlighted Maharashtra’s ‘Eat Right School’ initiative, which encourages children to adopt healthier eating habits, consume nutritious food and avoid excessive junk food. The programme has received encouraging feedback from parents, he said. FDA Steps Up Pharmaceutical Industry Inspections Mundhe also outlined the department’s enforcement efforts in the pharmaceutical sector, including action against establishments that fail to comply with regulatory requirements. Inspections cover pharmacies, drug manufacturing facilities and producers of active pharmaceutical ingredients (APIs), which are essential components of medicines. He said inspections had uncovered shortcomings at certain manufacturing facilities, including equipment affected by rust. The department is strengthening surveillance and enforcement to address such deficiencies and improve compliance across the pharmaceutical supply chain. The planned digital milk-tracking system, alongside inspections and awareness initiatives, is expected to support efforts to improve food safety standards and strengthen accountability across Maharashtra’s dairy sector. Source: PTI  

Maharashtra to Introduce Digital Milk Tracking System to Combat Adulteration Read More »

WHO Advises Against Obesity Drugs and Surgery for Children Under 10

The World Health Organization (WHO) has issued its first guidelines focused specifically on tackling obesity among children and adolescents, recommending lifestyle-based interventions rather than medicines or surgery for children under the age of 10. The global health agency said children aged 0 to 9 should not be treated with weight-loss medicines, bariatric surgery or weight-loss devices. Instead, it strongly recommends comprehensive programmes centred on healthy diets, regular physical activity and sustainable behavioural changes. For adolescents aged 10 to 19, approved obesity medicines may be considered in selected cases when supervised lifestyle programmes have failed to produce the desired results. Bariatric surgery may also be considered for adolescents with severe obesity, but only under strict conditions and appropriate medical supervision. The recommendations differ from WHO’s guidance for adults, which has recognised the potential role of newer weight-management medicines, including GLP-1 receptor agonists, in treating obesity. The scale of childhood obesity has become a growing global concern. WHO estimates that around 70 million children aged five to nine and approximately 100 million adolescents aged 10 to 19 were living with obesity in 2024. Among people aged five to 19, the global prevalence of obesity increased from about 2 per cent in 1990 to 8 per cent in 2024. WHO officials said the increase is being seen across regions, including low- and middle-income countries. The agency emphasised that the foundation of obesity care for young people should be access to nutritious food, physical activity and sustained support for healthier behaviours. The guidelines also highlight the importance of mental health. Anxiety, depression and low self-esteem can influence eating habits, physical activity and social behaviour. At the same time, children and adolescents living with obesity may face stigma, discrimination and bullying. WHO experts noted that bariatric surgery could be considered for some adolescents with severe obesity and related complications, such as type 2 diabetes or hypertension, particularly when lifestyle interventions have not been effective. Such cases require careful assessment and specialised medical supervision. Source: AFP Photo Credit: Reuters

WHO Advises Against Obesity Drugs and Surgery for Children Under 10 Read More »